Evidence map›Paper›PMID 34248472›Full record

ArticleBreast care (Basel, Switzerland)2021

Identification of a Prognostic Signature Based on the Expression of Genes Related to the Insulin Pathway in Early Breast Cancer.

Alessandra Gennari, Mariapia Sormani, Matteo Puntoni, Veronica Martini, Adriana Amaro, Paolo Bruzzi, Ulrich Pfeffer

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Breast care (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Alessandra GennariDivision of Oncology, Department of Translational Medicine, University of Eastern Piedmont, Novara, Italy.
Mariapia SormaniDISSAL, University of Genoa, Genoa, Italy.
Matteo PuntoniClinical Trial Unit, Galliera Hospital Genoa, Genoa, Italy.
Veronica MartiniDivision of Oncology, Department of Translational Medicine, University of Eastern Piedmont, Novara, Italy.
Adriana AmaroTumor Epigenetics, IRCCS Ospedale Policlinico San Martino, Genoa, Italy.
Paolo BruzziClinical Epidemiology, IRCCS Ospedale Policlinico San Martino, Genoa, Italy.
Ulrich PfefferTumor Epigenetics, IRCCS Ospedale Policlinico San Martino, Genoa, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionInsulin and the insulin-like growth factor (IGF) family play a key role in breast cancer (BC).

objectiveIn this study, we evaluated on a genomic scale the potential prognostic value of insulin signaling in early BC.

methodsCandidate genes were selected from the published literature and gene expression profiling experiments. Three publicly available BC datasets, containing gene expression data on 502 cases, were used to test the prognostic ability of the score. The gene signature was developed on GSE1456, containing microarray data from 159 patients, split into a training set (102 breast tumors) and a validation set (

resultsOn the training set, 15 genes turned out to be differentially expressed: 8-year disease-free survival (DFS) was 51 and 91% in the high- and low-risk group (

conclusionsOur findings indicate that the insulin pathway is involved in BC prognosis at a genomic level and provide a window of selectivity for preventive and treatment strategies targeting the insulin/IGF pathway in BC patients.

Indexed as

Early diseaseGene expressionInsulin-like growth factors

Identifiers

PMID34248472
PMCPMC8251663

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.